Bladder Cancer and Upper Tract Urothelial Carcinoma – Landscape & Forecast – Disease Landscape & Forecast (G7)

The treatment landscape for bladder cancer and upper tract urothelial carcinoma (UTUC) continues to evolve with the expanding role of immune checkpoint inhibitors and novel targeted therapies. The anti-PD-1 therapies Keytruda (Merck & Co.) and Opdivo (Bristol Myers Squibb) remain integral across multiple treatment lines, with Keytruda combined with the antibody-drug conjugate (ADC) Padcev (Pfizer / Astellas) poised as the first-line standard for cisplatin-ineligible patients. Bavencio (Merck KGaA / Pfizer) remains the only agent used in first-line maintenance therapy. Adstiladrin (Ferring Pharmaceuticals), the first gene therapy for high-risk non-muscle invasive bladder cancer, represents a key innovation, providing another treatment option. Balversa (Johnson & Johnson), the first FGFR inhibitor, offers targeted treatment for patients with FGFR3 alterations after a prior systemic therapy. This marks a shift toward biomarker-driven therapy. Emerging therapies, including novel targeted agents, will continue to diversify treatment options, intensifying market competition.

Questions answered

• What are the sizes of the clinically and commercially relevant drug-treatable populations in this market, and how will drug-treatment rates change over time?
• How are bladder cancer and UTUC treated, and how do their treatment options differ? What are the key advantages and limitations of therapies, and how have recent drug approvals impacted the treatment paradigm?
• Which emerging therapies are considered most promising, and what level of patient share uptake could they achieve?
• What are the key market drivers, constraints, and how is the market expected to evolve over the next 10 years?

Geography: United States, EU5, Japan

Primary research: Country-specific interviews with thought-leading urologists and medical oncologists; Survey data collected for this and other Clarivate research

Epidemiology: Incidence of bladder cancer and UTUC by country, segmented by clinically and commercially relevant drug-treatable and drug-treated patients

Forecast: 10-year, annualized, drug-level sales and patient share of key bladder cancer and UTUC therapies through 2034, segmented by brands / generics and epidemiological subpopulations

Drug treatments: Coverage of key current and late-phase emerging therapies

Product description

Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:

• Optimize your long-term disease and development strategy.
• Quantify market potential for your pipeline assets and those of your competitors.
• Understand a disease from top to bottom, including key patient populations, the current and future therapeutic landscape, and the evolving market trajectory.
• Gauge the commercial outlook and impact of key market events.